If you are experiencing problems downloading PDF or HTML fulltext, our helpdesk recommend clearing your browser cache and trying again. If you need help in clearing your cache, please click here . Still need help? Email help@ingentaconnect.com

Blockade of Chemokine-Mediated Tissue Injury in Lupus Nephritis

$71.00 plus tax (Refund Policy)

Buy Article:

Abstract:

Pro-inflammatory chemokines are important mediators of inflammation and autoimmune injury. The spatial and temporal expression of chemokines and chemokine receptors in the nephritic kidney suggests that targeting the chemokine system may represent a valuable approach for anti-inflammatory therapy of lupus nephritis. In this review we summarize the available data on the pathogenic role of chemokines and chemokine receptors in lupus nephritis and particularly focus on epidemiological data in lupus patients and interventional studies with chemokine or chemokine receptor antagonists in experimental lupus.





Keywords: Chemokine; MRL/lpr mouse; chemokine receptors; kidney; leukocyte recruitment; polymorphism; systemic lupus erythematosus

Document Type: Research Article

DOI: http://dx.doi.org/10.2174/187153006779025739

Affiliations: Medizinische Poliklinik Innenstadt, Ludwig-Maximilians-University, Pettenkoferstr. 8a, 80336 Munich, Germany.

Publication date: December 1, 2006

More about this publication?
  • This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders.
Related content

Tools

Favourites

Share Content

Access Key

Free Content
Free content
New Content
New content
Open Access Content
Open access content
Subscribed Content
Subscribed content
Free Trial Content
Free trial content
Cookie Policy
X
Cookie Policy
ingentaconnect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more